OncoMatch/Clinical Trials/NCT07259317
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Is NCT07259317 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Relacorilant 150 mg once daily (QD) and Nab-paclitaxel 100 mg/m^2 for adenocarcinoma.
Treatment: Relacorilant 150 mg once daily (QD) · Nab-paclitaxel 100 mg/m^2 · Gemcitabine 1000 mg/m^2 — This is a Phase 2, single-arm study to evaluate the safety and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (PDAC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Biomarker criteria
Excluded: BRCA1 mutation
Excluded: BRCA2 mutation
Disease stage
Required: Stage IV
Metastatic disease required
Radiographic confirmation of metastatic disease with at least 1 distant tumor metastasis measurable on radiology imaging per RECIST version 1.1 criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anticancer therapy
Exception: If a patient received prior treatment of PDAC with chemotherapy, disease progression must have occurred >12 months after completing the last dose, and no persistent treatment-related toxicities can be present.
Received no prior systemic anticancer therapy to treat metastatic disease
Cannot have received: radiotherapy
Radiotherapy ... for the treatment of metastatic disease
Cannot have received: surgery
surgery ... for the treatment of metastatic disease
Cannot have received: chemotherapy
chemotherapy ... for the treatment of metastatic disease
Cannot have received: immunotherapy
immunotherapy ... for the treatment of metastatic disease
Cannot have received: investigational therapy
investigational therapy for the treatment of metastatic disease
Cannot have received: chemotherapy (gemcitabine, nab-paclitaxel)
Received gemcitabine or nab-paclitaxel to treat their PDAC
Lab requirements
Blood counts
Adequate organ function
Kidney function
Adequate organ function
Liver function
Adequate organ function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Site 02 · Scottsdale, Arizona
- Site 04 · Los Angeles, California
- Site 06 · Atlanta, Georgia
- Site 03 · Grand Rapids, Michigan
- Site 05 · Lake Success, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify